A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners’ proprietary compounds. We are also developing partner products with Hypercon™ drug delivery technology (“Hypercon technology”) and developing the Surf Bio drug delivery technology to expand the breadth of our drug delivery technology portfolio.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.4B | 1.4B | 1.0B | 829M | 660M | 443M |
| Net Income | 317M | 317M | 444M | 282M | 202M | 403M |
| EPS | $2.56 | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 |
| Free Cash Flow | 645M | 645M | 468M | 373M | 235M | 298M |
| ROIC | 15.5% | 16.7% | 27.3% | 19.6% | 26.4% | 107.6% |
| Gross Margin | 56.4% | 56.4% | 84.3% | 76.8% | 78.9% | 77.8% |
| Debt/Equity | 43.89 | 43.89 | 4.14 | 17.89 | 8.87 | 4.45 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 469M | 469M | 551M | 338M | 268M | 276M |
| Operating Margin | 33.6% | 33.6% | 54.3% | 40.7% | 40.5% | 62.2% |
| ROE | 649.2% | 153.6% | 198.4% | 222.1% | 110.2% | 231.4% |
| Shares Outstanding | 124M | 124M | 129M | 134M | 140M | 147M |
HALOZYME THERAPEUTICS, INC. passes 7 of 9 quality checks, indicating strong fundamentals.
HALOZYME THERAPEUTICS, INC. trades at 26.2x trailing earnings, compared to its 15-year median P/E of 26.9x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 12.3x vs a median of 16.5x. The company's 5-year average ROIC is 39.5% with a gross margin of 74.8%. Total shareholder yield (buybacks) is 4.1%. At current prices, the estimated annualized return to fair value is +69.9%.
HALOZYME THERAPEUTICS, INC. (HALO) has a current P/E ratio of 26.2, compared to its historical median P/E of 26.9. The stock is currently considered Fair based on its historical valuation range.
HALOZYME THERAPEUTICS, INC. (HALO) has a 5-year average return on invested capital (ROIC) of 39.5%. This indicates strong capital allocation and a potential competitive advantage.
HALOZYME THERAPEUTICS, INC. (HALO) has a market capitalization of $8.3B. It is classified as a mid-cap stock.
HALOZYME THERAPEUTICS, INC. (HALO) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 4.13%.
Based on historical P/E analysis, HALOZYME THERAPEUTICS, INC. (HALO) appears fair. The current P/E of 26.2 is 3% below its historical median of 26.9. The estimated fair value CAGR (P/E method) is 46.2%.
HALOZYME THERAPEUTICS, INC. (HALO) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
HALOZYME THERAPEUTICS, INC. (HALO) reported annual revenue of $1.4 billion in its most recent fiscal year, based on SEC EDGAR filings.
HALOZYME THERAPEUTICS, INC. (HALO) has a net profit margin of 22.7%. This is a strong margin indicating high profitability.
HALOZYME THERAPEUTICS, INC. (HALO) generated $645 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
HALOZYME THERAPEUTICS, INC. (HALO) has a debt-to-equity ratio of 43.89. This indicates higher leverage, which may increase financial risk.
HALOZYME THERAPEUTICS, INC. (HALO) reported earnings per share (EPS) of $2.56 in its most recent fiscal year.
HALOZYME THERAPEUTICS, INC. (HALO) has a return on equity (ROE) of 153.6%. This indicates the company generates strong returns for shareholders.
HALOZYME THERAPEUTICS, INC. (HALO) has a 5-year average gross margin of 74.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for HALOZYME THERAPEUTICS, INC. (HALO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
HALOZYME THERAPEUTICS, INC. (HALO) has a book value per share of $0.39, based on its most recent annual SEC filing.